Nexalin Regains Nasdaq Compliance but Faces Equity Deadline…

Event summary

Nexalin's stock price remained above $1.00 for 21 consecutive trading days (August 31–September 29, 2026), regaining Nasdaq compliance.
Nasdaq Hearings Panel granted continued listing but requires $2.5M stockholders' equity by January 4, 2027.
CEO Mark White highlights South American distribution deal and U.S. clinical trial progress as strategic priorities.
Company must notify Nasdaq of any events affecting compliance during exception period.

The big picture

Nexalin's compliance win is tempered by the looming equity deadline, reflecting the precarious balance small-cap medical device companies face between regulatory requirements and commercialization timelines. The company's focus on international expansion and U.S. clinical trials underscores the dual-track strategy common among neurotechnology firms seeking both near-term revenue and long-term regulatory validation.

What we're watching

Equity Compliance: Whether Nexalin can meet the $2.5M stockholders' equity requirement by January 4, 2027, to avoid delisting.
Commercial Momentum: The pace at which South American distribution agreements translate into revenue amid U.S. clinical trial progress.
Regulatory Pathway: How FDA marketing authorization for DIFS technology will impact long-term market positioning.